Premium
Multidrug resistance proteins preferentially regulate natriuretic peptide‐driven cGMP signalling in the heart and vasculature
Author(s) -
Grange Robert M. H.,
Preedy Michael E. J.,
Renukanthan Aniruthan,
Dignam Joshua P.,
Lowe Vanessa J.,
Moyes Amie J.,
PérezTernero Cristina,
Aubdool Aisah A.,
Baliga Reshma S.,
Hobbs Adrian J.
Publication year - 2022
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.15593
Subject(s) - atrial natriuretic peptide , in vivo , natriuretic peptide , pharmacology , heart failure , npr1 , medicine , brain natriuretic peptide , endocrinology , biology , microbiology and biotechnology
cGMP underpins the bioactivity of NO and natriuretic peptides and is key to cardiovascular homeostasis. cGMP-driven responses are terminated primarily by PDEs, but cellular efflux via multidrug resistance proteins (MRPs) might contribute. Herein, the effect of pharmacological blockade of MRPs on cGMP signalling in the heart and vasculature was investigated in vitro and in vivo.